871025-06-8

Basic information

• Product Name: 6-(furan-2-yl)-5H-pyrrolo[3,2-d]pyriMidin-4-ol
• Synonyms: 6-(furan-2-yl)-5H-pyrrolo[3,2-d]pyriMidin-4-ol;6-(Furan-2-yl)-3H-pyrrolo[3,2-d]pyriMidin-4(5H)-one
• CAS NO: 871025-06-8
• Molecular Formula: C₁₀H₇N₃O₂
• Molecular Weight: 201.18148
• Mol File: 871025-06-8.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-(furan-2-yl)-5H-pyrrolo[3,2-d]pyriMidin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(furan-2-yl)-5H-pyrrolo[3,2-d]pyriMidin-4-ol(871025-06-8)
• EPA Substance Registry System: 6-(furan-2-yl)-5H-pyrrolo[3,2-d]pyriMidin-4-ol(871025-06-8)

Safety Data

• Hazardous Substances Data: 871025-06-8(Hazardous Substances Data)

Usage

Description

6-(furan-2-yl)-5H-pyrrolo[3,2-d]pyrimidin-4-ol, also known as Olaparib, is a pyrrolopyrimidine chemical compound that functions as a potent inhibitor of the enzyme poly (ADP-ribose) polymerase (PARP). It is primarily utilized as a targeted therapy for treating specific types of cancer, such as ovarian and breast cancer. Olaparib's mechanism of action involves blocking the PARP enzyme, which is crucial for DNA repair, thereby causing the accumulation of DNA damage and leading to the death of cancer cells. This orally administered compound has demonstrated promising results in clinical trials, showing its potential to enhance progression-free survival and overall survival in cancer patients携带特定遗传突变.

Uses

Used in Oncology:
Olaparib is used as an anticancer agent specifically for the treatment of ovarian and breast cancer. Its application is particularly beneficial for patients with specific genetic mutations, as it has been shown to improve progression-free survival and overall survival rates in clinical trials.
Used in Targeted Cancer Therapy:
As a targeted therapy, 6-(furan-2-yl)-5H-pyrrolo[3,2-d]pyrimidin-4-ol is used to inhibit the PARP enzyme, which plays a significant role in DNA repair mechanisms within cancer cells. By blocking this enzyme, the compound leads to the accumulation of DNA damage, ultimately inducing cell death and offering a precision approach to cancer treatment.
Used in Pharmaceutical Development:
Olaparib serves as a key compound in the development of pharmaceuticals for cancer treatment. Its success in clinical trials highlights the importance of targeted therapies in oncology and encourages further research into similar compounds that can be tailored to address specific genetic mutations and cancer types.

Upstream product

• 3473-63-0 formamidine acetic acid 
• 237435-96-0 ethyl 3-amino-5-(2-furanyl)-1H-pyrrole-2-carboxylate 

Downstream Products

• 871025-07-9 4-chloro-6-(furan-2-yl)-5H-pyrrolo[3,2-d]pyrimidine 

Relevant articles and documents

FUSED HETEROCYCLIC COMPOUND

The present invention relates to a compound represented by the formula: wherein W is C(R 1 ) or N, each A is an optionally substituted aryl group or a heteroaryl group, X 1 is -NR 3 -Y 1 -, -O-, -S-, -SO-, -SO 2 or -CHR 3 - wherein R 3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R 3 is optionally bonded to A to form an optionally substituted ring structure, R 1 is a hydrogen atom or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom, R 2 is a hydrogen atom or optionally substituted group bonded via a carbon atom or a sulfur atom, or R 1 and R 2 , or R 2 and R 3 are optionally bonded to form an optionally substituted ring structure, or a salt thereof, and a tyrosine kinase inhibitor or an agent for the prophylaxis or treatment of cancer, which contains this compound or a prodrug thereof.